Application of a miR-3131 inhibitor in the preparation of medicines
MiR-3131 inhibitor targets cerebral arteriovenous malformation with KRAS mutation, inhibits endothelial mesenchymal transformation, and provides alternative surgical treatment drug solutions, solving the problem of lack of effective drugs in the prior art to treat cerebral arteriovenous malformation, and achieving Effective treatment of KRAS mutation bAVM.
Patent Information
- Application Number
- CN202211182452.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-27
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art lacks effective drugs to treat cerebral arteriovenous malformations, resulting in patients relying on high-risk surgical treatment.
MiR-3131 inhibitor was used as a drug to target cerebral arteriovenous malformations of KRAS mutations and KRASG12D mutations, inhibit endothelial mesenchymal transformation (EndMT). Drugs were prepared by miR-3131 inhibitors, and bAVM endothelial cells with KRAS mutations were treated.
Effectively inhibiting endothelial mesenchymal transformation in cerebral arteriovenous malformations caused by KRAS mutations provides an alternative surgical treatment drug regimen to reduce the damage to the patient's body and the risk of surgery.
Smart Images

Figure CN115844918B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and more specifically, to the use of miR-3131 inhibitors in the preparation of drugs. Background Art
[0002] Brain arteriovenous malformations (bAVMs) are rare vascular lesions with the main pathological feature that there is no normal capillary bed between the arteries and veins. The arteries and veins are directly connected, so that the arterial blood does not pass through the capillary bed but flows directly into the drainage vein. Brain arteriovenous malformations usually occur in young people and manifest as epileptic seizures, neurological deficits, headaches or destructive spontaneous intracranial hemorrhage.
[0003] At present, the main clinical treatments for brain arteriovenous malformations include microneurosurgical treatment, intravascular interventional embolization, and combined surgical treatment. The above methods are all surgical treatments. Compared with drug treatment, surgical treatment is more harmful to the patient's body and has a high surgical risk. However, there is currently no effective drug for brain arteriovenous malformations. Therefore, there is an urgent need for a drug that can treat brain arteriovenous malformations to replace surgical treatment. Summary of the invention
[0004] In order to solve the above technical problems, the present invention provides a use of a miR-3131 inhibitor in the preparation of a drug, which can effectively treat cerebral arteriovenous malformations.
[0005] An embodiment of the present invention provides an application of a miR-3131 inhibitor in preparing a drug, the application comprising: application of the miR-3131 inhibitor in preparing a drug for treating cerebral arteriovenous malformations, the gene sequence of the miR-3131 inhibitor being shown in SEQ ID NO: 1 in the sequence table.
[0006] Specifically, the drug is a drug that inhibits KRAS mutated cerebral arteriovenous malformations.
[0007] Specifically, the drug is a drug that inhibits endothelial-mesenchymal transition in KRAS-mutated cerebral arteriovenous malformations.
[0008] Specifically, the drug is a KRAS inhibitor G12D Drugs for endothelial-mesenchymal transition in mutant cerebral arteriovenous malformations.
[0009] The embodiment of the present invention provides a use of a miR-3131 inhibitor in the preparation of a drug, wherein the miR-3131 inhibitor can be used to prepare a drug for treating KRAS G12DDrugs for inhibiting EndMT of bAVM endothelial cells with KRAS mutations, specifically, miR-3131 inhibitors can be used to prepare drugs for inhibiting EndMT of bAVM endothelial cells with KRAS mutations, further, miR-3131 inhibitors can be used to prepare drugs for treating bAVM with KRAS mutations, and further, miR-3131 inhibitors can be used to prepare drugs for treating bAVM.
[0010] Other features and advantages of the present invention will be described in the following description, and partly become apparent from the description, or understood by practicing the present invention. The purpose and other advantages of the present invention can be realized and obtained by the structures particularly pointed out in the description, claims and drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] The accompanying drawings are used to provide a further understanding of the technical solution of the present invention and constitute a part of the specification. Together with the embodiments of the present application, they are used to explain the technical solution of the present invention and do not constitute a limitation on the technical solution of the present invention.
[0012] Figure 1 This is a graph showing the results of Western blot analysis of the miR-3131 inhibitor provided in an embodiment of the present invention on HUVECs treated with bAVM exosomes, in which GAPDH is used as a reference.
[0013] Figure 2 This is a comparison diagram of the western blot analysis of the miR-3131 inhibitor provided in the embodiment of the present invention on HUVEC treated with the transfection supernatant and the transfection supernatant, in which GAPDH is used as a reference.
[0014] Figure 3 This is a graph showing the results of Western blot analysis of bAVM endothelial cells of patient 2 using the miR-3131 inhibitor provided in an embodiment of the present invention. In the graph, GAPDH is used as a reference.
[0015] Figure 4 The miR-3131 inhibitor provided in the embodiment of the present invention is used for KRAS G12D and KRAS NC Comparison of HUVECs treated with exosomes derived from transfected HUVECs, with GAPDH as a reference.
[0016] Figure 5 miR-3131 inhibitors for KRAS G12D and KRAS NC Comparison of the effects of transfected HUVECs derived from transfected HUVECs and HUVECs treated with transfection supernatant, with GAPDH as a reference. DETAILED DESCRIPTION
[0017] In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below in conjunction with the drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0018] Example
[0019] An embodiment of the present invention provides an application of a miR-3131 inhibitor in preparing a drug, the application including: application of the miR-3131 inhibitor in preparing a drug for treating cerebral arteriovenous malformations, the gene sequence of the miR-3131 inhibitor is shown in SEQ ID NO: 1 in the sequence table, specifically: 5'-aaggcccuuccaccaguccucga-3'.
[0020] Specifically, the drug is a drug that inhibits KRAS-mutated cerebral arteriovenous malformations.
[0021] Specifically, the drug is a drug that inhibits endothelial-to-mesenchymal transition (EndMT) in KRAS-mutated cerebral arteriovenous malformations.
[0022] Specifically, the drug is a KRAS inhibitor G12D Drugs for EndMT in mutated brain arteriovenous malformations.
[0023] The specific steps for obtaining primary bAVM (Brain arteriovenous malformation) endothelial cells are as follows:
[0024] 1. Obtaining bAVM tissue: The 20 specimens of bAVM tissue used in this example were obtained from 20 bAVM patients (numbered as patient 1 to patient 20) in the Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University (Beijing, China). For research purposes, informed consent for the deposit of bAVM tissue in a bank was obtained. The collection of bAVM tissue for research purposes was approved by the Ethics Committee of Beijing Tiantan Hospital. The bAVM tissue was sealed in a sterile glass bottle filled with saline and transferred to the laboratory for isolation and culture.
[0025] 2. Isolation and culture of bAVM tissue: The bAVM tissue was washed with Dulbecco's phosphate buffered saline (DPBS, #D8537, Sigma, USA), cut into small cubes, mixed with 0.1% collagenase I (#C2674, Sigma, USA) and incubated at 37°C for 15 minutes for pre-digestion. The pre-digested bAVM tissue was filtered through a 100 μm cell filter (#352360, BD Biosciences, USA). The cell suspension passed through the cell filter was centrifuged at 300 × g for 3 minutes to obtain a precipitate, and then the precipitate was resuspended in endothelial culture medium (ECM, #1001, ScienCell, USA). The bAVMs endothelium was separated using anti-CD31 magnetic beads (#130-091-935, MiltenyiBiotec, Germany). The bAVMs endothelial cells were resuspended with ECM in a T75 flask (#3290, Corning, USA) to obtain primary bAVM endothelial cells, namely primary bAVMECs.
[0026] Whole exome and ddPCR validation of KRAS G12D mutation
[0027] DNA extraction and whole exome sequencing of primary bAVM endothelial cells were performed using commercially available kits (GentraPuregene, QIAGEN, Germany) to isolate genomic DNA from bAVM endothelial cells. Two methods were used to check the quality of the DNA. 1. DNA degradation and contamination were monitored on a 1% agarose gel, and the genomic DNA concentration was measured using a Qubit 2.0 fluorometer (Invitrogen, USA). A total of 0.6 μg of genomic DNA was used for library preparation for each sample. Sequencing libraries were generated using the Agilent SureSelect Human All Exon V6 kit (Agilent Technologies, USA) and index codes were added. The index-coded samples were clustered on the cBot Cluster Generation System using the HiSeq PE Cluster Kit (Illumina, USA). After clustering, clusters were generated, and the DNA libraries were sequenced on the Illumina HiSeq platform, generating 150bp double-end reads. KRAS was validated using ddPCR G12D Endothelial cell mutations. Ultimately, 6 of the 20 bAVM patients were found to have KRAS in their bAVM endothelial cells. G12D mutations, and the six patients were patient 1, patient 2, patient 3, patient 4, patient 10, and patient 18.
[0028] KRAS mutations can not only lead to widespread EndMT in bAVM endothelial cells, but also cause widespread EndMT due to the effects of KRAS mutant endothelial cells on non-mutated endothelial cells. EndMT is a process in which mature endothelial cells acquire mesenchymal cell characteristics, which is manifested by endothelial cell proliferation and invasion, endothelial cell junction disorder, and spindle shape formation. In the process of EndMT, the main feature is the increase of mesenchymal markers (such as Calponin, Vimentin, FN1, and α-SMA), which may or may not be accompanied by a decrease in endothelial markers (such as CD31). Since EndMT can cause a variety of diseases, including bAVM, regulating EndMT is an effective method for treating bAVM.
[0029] Intercellular communication through cell-cell contact or paracrine effects is considered a key process in vascular remodeling. Exosomes are natural nanocarriers and intercellular messengers that play a key role in regulating intercellular communication and are important mediators in the pathogenesis of vascular diseases. G12D Exosomes secreted by mutant bAVMs endothelial cells can promote EndMT in HUVECs (human umbilical vein endothelial cells).
[0030] Get KRAS G12D The specific method for exosomes from mutant bAVM endothelial cells (patient 2) is as follows:
[0031] KRAS G12D The mutated bAVM endothelial cells were cultured in exosome-depleted endothelial culture medium (ECM) for 48 hours and then passaged. The cells were cultured in a constant temperature incubator at 37°C and 5% CO2 for at least 7 days to obtain a culture supernatant. The exosomes in the culture supernatant were extracted. The method for extracting the exosomes included: centrifuging the culture supernatant at 3000×g for 15 minutes at 4°C, and then centrifuging at 10000×g for 30 minutes to remove cells and debris to obtain a supernatant. The supernatant was further filtered with a 0.22-μm filter (Millipore). The filtered supernatant was centrifuged at 110000×g for 90 minutes at 4°C to precipitate the exosomes, and the supernatant was discarded to obtain a precipitate. The precipitate was suspended in phosphate buffered solution (PBS) to obtain KRAS G12D Exosomes from mutant bAVM endothelial cells.
[0032] Get KRAS G12DSupernatant of bAVM endothelial cells (patient 2) with mutations in KRAS G12D After the mutant bAVM endothelial cells were fully grown, they were cultured in a 37°C, 5% CO2 constant temperature incubator for 48 hours to obtain KRAS G12D Mutant bAVM endothelial cell supernatants.
[0033] One portion of HUVEC was co-cultured with the obtained exosomes to obtain a first sample, and another portion of HUVEC was co-cultured with the obtained supernatant to obtain a second sample. The co-culture conditions were: culture and maintenance in a humid atmosphere, and transfection for 24 hours at 37°C and a 5% CO2 atmosphere. The HUVEC used in this example was commercially available HUVEC (#8000, ScienCell, USA).
[0034] The miR-3131 inhibitor was added to the first sample and the second sample respectively (using the standard procedure of the lipo 3000 kit, the miR-3131 inhibitor was mixed with 5ul of lipo 3000 at a concentration of 100mM, the medium was changed after 4 hours, and the culture was continued for 48 hours). The changes of the mesenchymal markers Calponin, Vimentin, FN1 and α-SMA of HUVEC transfected with exosomes and transfection supernatant were detected by Western blotting to reflect the situation of EndMT. Specifically, the method of Western blotting includes: extracting proteins with radioimmunoprecipitation assay lysis buffer (Sigma, USA) and quantifying them with a bicinchoninic acid protein assay kit (KeyGen, China). Equal amounts of cell lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride transfer membrane (Millipore, USA). The polyvinylidene fluoride transfer membrane was blocked at room temperature for 1 hour, immunoblotted with antibodies overnight at 4°C, and then incubated with secondary antibodies. The bands were visualized using Pierce electrochemiluminescent protein blotting substrate (Thermo Fisher Scientific, USA). Figures 1 to 3 As shown. Combined Figures 1 to 3 It can be seen that miR-3131 inhibitor reversed the effects of KRAS G12D Exosomes and supernatants of transfected HUVECs showed increased levels of mesenchymal markers, suggesting that miR-3131 inhibitors can be used to prepare therapeutics for KRAS G12D Drugs for inhibiting EndMT of bAVM endothelial cells with KRAS mutations, specifically, miR-3131 inhibitors can be used to prepare drugs for inhibiting EndMT of bAVM endothelial cells with KRAS mutations, further, miR-3131 inhibitors can be used to prepare drugs for treating bAVM with KRAS mutations, and further, miR-3131 inhibitors can be used to prepare drugs for treating bAVM.
[0035] HUVECs were cultured with commercially available KRAS G12D The third and fourth samples were obtained by transfection with lentivirus and commercially available control lentivirus (Hesheng Gene, China). The transfection conditions were as follows: culture and maintenance in a humid atmosphere at 37°C and a 5% CO2 atmosphere. After transfection for 24 hours at an MOI of 20, the medium was replaced with ECM complete medium (#1001, Sciencell, China). After 24 hours of medium replacement, screening was performed using ECM complete medium containing 2 units of puromycin (lentivirus carries a puromycin resistance gene, and the growth of successfully transfected cells is not affected by the expression of the gene, while unsuccessfully transfected cells die). After 2 days, the successfully transfected cells were amplified and subsequent experiments were performed.
[0036] The miR-3131 inhibitor was added to the third and fourth samples respectively (using the standard procedure of the lipo 3000 kit, the miR-3131 inhibitor was mixed with 5ul of lipo 3000 at a concentration of 100mM, the medium was changed after 4 hours, and the culture was continued for 48 hours), and the effect of the miR-3131 inhibitor on HUVEC was identified by Western blotting and immunofluorescence staining. The results are shown in Figure 4 and Figure 5 As shown. Figure 4 Compared with the negative control, miR-3131 inhibitor reversed the expression of KRAS G12D Levels of mesenchymal markers in exosomes of transfected HUVEC. Figure 5 Compared with the negative control, miR-3131 inhibitor reversed the expression of KRAS G12D The levels of mesenchymal markers in the transfected supernatant of transfected HUVEC cells. It can be seen that the miR-3131 inhibitor affects the communication between KRAS mutant endothelium and normal endothelium, that is, it affects EndMT, further proving that miR-3131 inhibitors can be used to prepare therapeutic drugs for KRAS G12D Drugs for inhibiting EndMT of mutant bAVM endothelial cells, specifically, miR-3131 inhibitors can be used to prepare drugs for inhibiting EndMT of KRAS mutants.
[0037] Although the embodiments disclosed in the present invention are as above, the contents described are only embodiments adopted to facilitate understanding of the present invention and are not intended to limit the present invention. Any technician in the field to which the present invention belongs can make any modifications and changes in the form and details of implementation without departing from the spirit and scope disclosed in the present invention, but the patent protection scope of the present invention shall still be subject to the scope defined in the attached claims.
Claims
1. Use of a miR-3131 inhibitor in the preparation of a drug, characterized in that: The application is: the miR-3131 inhibitor is used in the preparation of a KRAS G12D The invention relates to a drug for treating mutated cerebral arteriovenous malformations, wherein the gene sequence of the miR-3131 inhibitor is shown as SEQ ID NO: 1 in the sequence table.
Citation Information
Patent Citations
Materials and methods for treatment of pain related disorders
CN109843914A
Probe having false positive suppression function, design method therefor, and usage therefor
CN110325639A
Application of using miR-3131 as biomarker for predicting cerebral arteriovenous malformation
CN115976186A
Oligonucleotide probes and uses thereof
WO2016081941A1
